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Glucocorticoid hormones (GCs) play a pivotal role in many stress-related biological 
processes. In the hippocampus, GCs act through mineralocorticoid (MRs) and glucocorticoid 
receptors (GRs) to modify gene transcription. Involvement of GCs in biological processes has 
been studied using the corticosterone (CORT)-synthesis blocker metyrapone. How 
metyrapone affects GC action at the genomic level is however still unclear. Therefore, we 
studied the effects of this enzyme blocker on plasma CORT levels and hippocampal MR and 
GR binding to GC responsive elements (GREs) within the GC target genes Fkbp5 (FK506-
binding protein 5), Per1 (Period 1) and Sgk1 (Serum- and glucocorticoid-activated kinase 1), 
as well as transcriptional responses of these genes under control and acute stress conditions 
in rats. For comparison, we also studied these endpoints in adrenalectomized (ADX) rats. 
Although metyrapone had no effect on baseline levels of CORT, the drug increased MR and 
GR to GRE binding within the GC target genes and the transcriptional activity of these genes. 
As expected, acute forced swim (FS) stress strongly increased plasma CORT levels, 
hippocampal MR and GR to GRE binding within Fkbp5, Per1 and Sgk1, and transcriptional 
activity (mainly hnRNA levels) of these genes.  Metyrapone attenuated, but not abolished, 
these effects of stress on plasma CORT and MR and GR to GRE binding. The drug effects on 
FS-induced transcriptional activity were gene-dependent with a reduction seen in Fkbp5 
hnRNA (but not Fkbp5 mRNA), an enhancement in Per1 hnRNA (but not Per1 mRNA), and no 
effect on both Sgk1 hnRNA and mRNA levels. ADX however completely abrogated the 
effects of FS on plasma CORT as well as hippocampal MR and GR to GRE binding and 
transcriptional responses.  
Thus, in contrast to ADX, metyrapone produced inconsistent effects on GC-sensitive 







Metyrapone, adrenalectomy, mineralocorticoid receptor, glucocorticoid receptor, gene 





 Glucocorticoid hormones (GCs) are essential for appropriate responses to stressful 
challenges and thereby support adaptation and survival [1]. They fulfil this vital role by acting 
on numerous biological processes, including metabolism, the immune system and the central 
nervous system [2-3]. Dysregulation of GC secretion as a result of hypothalamic-pituitary-
adrenal (HPA) axis malfunction, as often seen under chronic stress conditions, is thought to 
be strongly linked to a number of neuropsychiatric disorders such as major depression, 
anxiety-related disorders, post-traumatic stress disorder (PTSD) and schizophrenia [4-7]. 
Presently, the exact role of GCs in the aetiology of these disorders is still unclear. Therefore, 
insight into the molecular mechanisms underpinning GC action in the brain is of critical 
importance.  
Endogenous GCs (corticosterone (CORT) in rodents like rats and mice) bind to two types of 
intracellular receptors, the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR), 
which are both found in relatively high concentration in the hippocampus [8, 9] and are 
known to act as ligand-dependent transcription factors. Recently, we found that an acute 
stressful challenge results in a substantial rise in the binding of MRs and GRs to glucocorticoid 
response elements (GREs) in the DNA leading to enhanced  transcriptional activity of the GC 
target genes FK506-binding protein 5 (Fkbp5),  Period 1 (Per1) and  Serum- and glucocorticoid-
activated kinase 1 (Sgk1) [14]. The genomic action of MRs and GRs is thought to underlie many 
GC-dependent behavioural and physiological changes observed after stress or associated with 
circadian rhythm [10].  
As stress exerts its effects on physiology and behaviour via multiple mediators, an 
investigation into the role of endogenous GCs in stress-induced responses would require 




an inhibitor of the enzyme 11-β-hydroxylase (thus, preventing the conversion of 
deoxycorticosterone to CORT [11]), has been used to block endogenous GC synthesis in 
behavioural paradigms [12, 13]. Until now, however, the consequences of metyrapone 
administration on the molecular effects of GCs at the genomic level have not been 
investigated. Therefore, we decided to study the effects of this enzyme inhibitor on MR and 
GR binding to GREs within the Fkbp5, Per1 and Sgk1 genes in the hippocampus under early 
morning baseline and acute stress condition using chromatin immuno-precipitation (ChIP). In 
addition, we investigated the effect of metyrapone on baseline and stress-induced 
transcriptional responses of these genes. In these studies, we could take advantage of our 
recent characterization of MR/GR GRE-binding and transcriptional responses under baseline 
and acute stress conditions with regard to these GC target genes [14]. Our experiments 
revealed effects of metyrapone which were contradictory to the expected, GC-reducing 
effects of the drug. In light of these findings, we decided to additionally investigate the effects 
of complete removal of endogenous GCs by bilateral adrenalectomy (ADX). We found that 
ADX indeed completely abolished the effects of stress on MR/GR GRE-binding and Fkbp5, Per1 
and Sgk1 transcriptional responses. This work shows that when using metyrapone 
unexpected effects at the genomic level need to be taken into account that may preclude 






Materials and Methods 
Animals 
Male Wistar rats (150-175 g) were purchased from Harlan and group-housed (two to three 
animals per cage). Animals were kept under standard light (lights on 5:00–19:00; 80–100 Lux) 
and environmentally controlled conditions (temperature 21 ± 1 °C; relative humidity 40–60%) 
with food and water available ad libitum. All procedures were approved by the University of 
Bristol Ethical Committee and by the Home Office of the United Kingdom (Animal Scientific 
Procedures Act, 1986, UK). Except for the day of the experiment, all rats were handled (2 min 
per rat per day) to reduce any nonspecific stress effects. 
Drug Treatment  
Rats were intraperitoneally (i.p.) injected either once or twice at 90-min intervals with the 11-
β-hydroxylase inhibitor metyrapone (100 mg/kg i.p., as indicated). As a control condition, the 
same amount of vehicle (40% PEG, 60% 0.9%-saline; 1 ml/kg i.p.) was injected at 
corresponding intervals. Following the injection protocol, some animals were subjected to 
forced swimming (see below). Full details of dosing schedule and experimental regimens can 
be found in Supplementary Figure 1 and in the legends to the figures. All drugs and chemicals 
were purchased from Sigma-Aldrich (Poole, UK). 
Surgical Procedures 
Some rats underwent bilateral ADX or sham surgery. Surgeries were performed under 
isoflurane anaesthesia. Sham surgeries were identical to ADX except that the adrenals were 




mg/l) in their drinking water for 1 week following surgery. One-week post-surgery, CORT 
supplementation was discontinued 1 day before experimentation. 
Animal experimentation and collection of hippocampus tissue and blood 
All animal experiments were conducted between 8:00 and 12:00. Rats were acutely stressed 
by forced swimming (15 min in 25 °C water) in individual glass beakers (height 35 cm, 
diameter 21.7 cm). Depending on the protocol (see Suppl. Fig. 1 and legends to the figures), 
rats were either naïve (i.e. untouched), injected once or twice with metyrapone of vehicle, or 
had been adrenalectomized or sham-adrenalectomized. Rats were killed under baseline (non-
FS) conditions or killed 30 min (FS30) or 60 min (FS60) after the start of forced swimming (see 
legends). Rats that were injected but not forced to swim, were killed at the corresponding 
time after injection. For ChIP experiments, animals were killed at FS30 as 30 min after the 
start of FS stress was the time at which MR and GR binding to GREs with Fkbp5, Per1 and Sgk1 
was maximal [14]. For RNA experiments, rats were killed at 60 min post-FS, i.e. the time of 
maximal hnRNA or mRNA responses after stress [14].  
Rats were killed by decapitation following brief (<10 s) isoflurane anaesthesia after which 
trunk blood was collected in EDTA-containing tubes. The hippocampus was rapidly dissected 
on an ice-filled steel box and snap-frozen in liquid N2. The blood was spun down at 4 °C to 
prepare plasma. Tissue and plasma samples were stored at -80 °C until analysis. 
CORT Radioimmunoassay (RIA) 
Plasma CORT concentrations were measured using a commercial CORT RIA Kit (MP 
Biomedicals) as described previously [14]. 




ChIP was performed as previously described [14, 15]. We added 1 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF) or 0.1 mM PMSF, 5 mM Na+-Butyrate 
(NaBut), and PhosSTOP Phosphatase Inhibitor Mixture Tablets (Roche) to all solutions unless 
otherwise stated. Briefly, hippocampus tissues were cross-linked for 10 min in 1% 
formaldehyde in PBS at room temperature (RT). Cross-linking was terminated by addition of 
glycine (5 min, RT; final concentration: 200 μM) and centrifugation (5 min at 6,000 × g at 4 
°C). Pellets were washed three times with ice-cold PBS. Next, the pellets were resuspended 
in ice-cold lysis buffer [50 mM Tris HCl pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% (vol/vol) Igepal, 
0.5% Na-deoxycholate, 1% SDS, 2mM AEBSF,1 mM Na3VO4, Complete Ultra EDTA-Free 
Protease Inhibitor Tablets (one per 10 ml; Roche)] and rotated for 15 min at 4 °C. Samples 
were aliquoted, sonicated (high power; 3 × 10 cycles; 30 s on and 60 s off) using a water-
cooled (4°C) Bioruptor (UCD-300; Diagenode), and centrifuged (10 min at 20,000 × g at 4 °C). 
Supernatants (containing the sheared chromatin) were recombined and re-aliquoted into 
fresh tubes for subsequent ChIP analysis and assessment of input DNA (i.e., the DNA starting 
material). For ChIP analysis, aliquots of chromatin were diluted 10-times in ice-cold dilution 
buffer [50 mM Tris HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, pH 8.0, 1% (vol/vol) Triton, 0.1% 
Na-deoxycholate, 1 mM AEBSF, Complete Ultra EDTA-Free Protease Inhibitor Tablets (one per 
10 mL; Roche)]. Ten microliters MR (MR H-300; sc11412X; Santa Cruz) or GR (GR H-300, 
sc8992X; Santa Cruz) antibody was added to each sample, and tubes were rotated overnight 
at 4 °C. The anti-MR and anti-GR antibodies had previously been validated in pre-absorption 
experiments and Western blotting [14]. Protein A-coated Dynabeads (Life Technologies) were 
washed once in ice-cold 0.5% BSA/PBS before blocking overnight at 4 °C. Pre-blocked beads 
were washed once in ice-cold Tris-EDTA buffer. Bound DNA was eluted in two steps at RT: 




with 100 μl elution buffer 2 (10 mM Tris HCl, pH 7.4, 50 mM NaCl, 0.5% SDS). Cross-links were 
reversed by addition of NaCl (final concentration 200 mM) and overnight incubation at 65 °C. 
The next day, samples were incubated first with RNase A (60 μg/mL, 37 °C, 1 h) followed by 
incubation with proteinase K (250 μg/mL, 37 °C, 3.5 h). DNA was purified using a QIAquick 
PCR Purification Kit (Qiagen) as per the manufacturer’s instructions. Input samples were 
incubated overnight at 65 °C in 200 mM NaCl to reverse cross-links and incubated with RNase 
A and proteinase K (over-night), and DNA was purified using a QIAquick PCR Purification Kit 
(Qiagen). Total dsDNA content was determined with a High-Sensitivity Qubit DNA Assay Kit 
(Life Technologies) as per the manufacturer’s instructions and quantified using a Qubit 2.0 
Fluorometer. All samples (bounds and inputs) were diluted to a standardized concentration 
with nuclease-free water and analyzed by qPCR as described below. A standard curve, created 
from serial dilutions of rat brain genomic DNA (Biochain), was included in each qPCR run for 
sample quantification. Data are expressed as quantity of bound DNA divided by the respective 
quantity of input DNA (i.e., B/I), which is a measure of the enrichment of steroid receptor 
bound to specific genomic sequences. 
RNA extraction 
RNA was extracted as described previously [14] using TRI Reagent (Sigma) following the 
manufacturer’s guidelines and quantified using a NanoPhotometer P300 (Implen). 260/280 
absorbance ratios, as an index of RNA purity, were consistently >2 and RNA integrity (RIN 
numbers) were >7.5 indicating the presence of intact RNA. Total RNA was reverse-transcribed 
into cDNA as per the manufacturer’s instructions using the QuantiTect Reverse Transcription 
Kit (Qiagen; 15 min, 42 °C; 5 min, 95 °C) or using GoScript™ Reverse Transcription System 




T1000 Thermal Cycler. cDNA was diluted four-fold in nuclease-free water and 2 μl diluted 
cDNA was used per reaction in the qPCR analysis detailed below. Expression of hnRNA or 
mRNA in samples was calculated based on the Pfaffl method of relative quantification [16] 
using primer/probes as previously published [14] and standardized to the expression of 
house-keeping genes (HKGs) hypoxanthine phosphoribosyltransferase 1 (Hprt1) and tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta (Ywhaz). These 
genes were selected as HKGs due to their stability across experimental groups (Suppl. Fig. 2 
(metyrapone experiment) & 3 (ADX experiment)). The data were expressed as fold change 
relative to the relevant control condition. 
qPCR Analysis 
Mastermix for qPCR was prepared containing 900 nM forward and reverse primers, 200 nM 
probe, and 1×TaqMan Fast Mastermix (Life Technologies) and made up to volume with nfH2O 
(nuclease-free H2O). Primers and dual-labelled probe with 6-Carboxyfluorescein (6-FAM) as 
the fluorescent dye and tetra-methylrhodamine (TAMRA) as the quencher were designed 
using Primer Express software (version 3.0.1; Life Technologies). Standard curves were 
performed for each primer pair, and the qPCR efficiency was calculated using the equation E 
= ((10 − 1/slope) − 1) × 100 (where E is qPCR efficiency, and the slope is the gradient of the 
standard curve). Only primer pairs with efficiencies greater that 90% were used. qPCR was 
performed using a StepOne Plus Machine (Life Technologies). TaqMan enzymes were 
activated at 95 °C for 20 s, and then, 40 cycles of 95 °C (1 s) to 60 °C (20 s) to amplify samples.  
Statistical Analysis 
Data were statistically analyzed using GraphPad Prism 8 software. Results are presented as 




analyzed with two-way ANOVA. If significant, post-hoc Bonferroni tests were conducted. 
Results of the statistical analyses are provided in the legends to the figures. P<0.05 was 





Effect of metyrapone treatment on FS-induced plasma CORT and hippocampal MR and GR 
to GRE binding levels 
Rats were injected once or twice with metyrapone (100mg/kg) or vehicle and killed under 
non-stress control conditions or at 30 min after the start of a 15min FS session (FS30). Figure 
1 shows the changes in plasma CORT and MR and GR to GRE binding to the GC-responsive 
genes Fkbp5, Per1 and Sgk1 in the hippocampus. Metyrapone did not affect the control levels 
of plasma CORT. As expected, FS resulted in a strong hormone response (Fig. 1A; for statistical 
data, see the legends to the figures) reaching similar levels as previously reported by us in 
naïve rats [14]. Pre-treatment with metyrapone significantly attenuated the FS-induced CORT 
response but even after two metyrapone injections a residual stress effect was observed (Fig. 
1A).  
Overall, FS evoked an increase in the binding of MR and GR to GREs within the three targeted 
genes in the hippocampus (Fig. 1B-G) which is in agreement with our previous observations 
[14]. Metyrapone treatment led to significant reductions in stress-induced MR and GR binding 
to GREs, in particular with regard to receptor binding to GREs within Fkbp5 and Per1. Except 
for the binding of MR to Fkbp5 and Sgk1 (Fig. 1B, F), it appeared that the dual metyrapone 
injection resulted in a loss of the FS-induced increases of MR and GR to GREs (Fig. 1C, D, E, G). 
The data in Figure 1 also indicate that metyrapone exerts distinct effects depending on 
whether rats were killed under control or stress conditions. This observation was statistically 
supported by the significant interaction terms of the two-way ANOVA analyses on the data in 
Fig. 1B-G. Whereas metyrapone overall resulted in reductions in stress-induced MR and GR 




binding in the control condition (see Fig. 1B, C, D, F). With regard to GR binding to Per1 and 
Sgk1, a trend (P=0.09, Bonferroni post-hoc test) towards an increased binding was observed 
after two drug injection under control conditions (Fig. 1E, G). Thus, it appears that after two 
metyrapone injections, MR and GR binding reach levels which are indiscriminate between 
control and stress conditions.  
 
Effect of metyrapone treatment on FS-induced plasma CORT and hippocampal GC target 
gene expression 
In view of the more potent effects of dual metyrapone injections, we decided to use this 
condition when studying drug and stress effects on the expression of the Fkbp5, Per1 and 
Sgk1 genes in the hippocampus. As a control condition for the dual drug treatment, we 
conducted dual injections of the vehicle. Thus, as described in the Methods and depicted in 
Suppl. Fig. 1, we injected rats twice with vehicle or metyrapone (100mg/kg i.p.) and killed 
them under non-stress control conditions or at 60min after start of FS (FS60). The FS60 time 
point was chosen as this was the peak time for Fkbp5, Per1 and Sgk1 hnRNA or mRNA [14]. In 
the vehicle-injected animals, FS resulted in a significant increase in plasma CORT levels at 
60min compared with control animals, similar to levels reported by us before [14]. In the 
metyrapone-treated rats, no significant stress-induced increase in plasma hormone levels at 
this time point could be observed compared with the drug-treated controls (Fig. 2A). 
Furthermore, no significant effect of the drug on CORT levels in control animals was found at this 
time point (Fig. 2A).  
FS significantly enhanced the hippocampal hnRNA expression of Fkbp5, Per1 and Sgk1 (Fig. 




to FS at FS120 but not at FS60 [14]. Metyrapone treatment produced differential effects on 
control and stress-induced RNA levels. In the control rats, the dual drug treatment resulted in 
significant increases in the levels of all hnRNAs and mRNAs of the investigated GC-target 
genes (Fig. 2B-G). We observed, however, gene-dependent effects after stress and drug 
treatment. With regard to Fkbp5, metyrapone treatment strongly attenuated the stress-
induced increase in hnRNA levels but slightly, albeit significantly, increased the mRNA levels 
(Fig. 2B, C). In both instances, the attained Fkbp5 RNA levels were not different from the 
respective levels in the drug-treated control animals (Fig. 2B, C). Per1 hnRNA levels were 
significantly higher in the metyrapone-treated rats after FS when compared with the 
corresponding vehicle-treated animals whereas there were no differences in the stress-
evoked mRNA responses (Fig. 2D, E). FS stress evoked significant increases in both hnRNA and 
mRNA levels of Sgk1 in the vehicle-treated rats (Fig. 2F, G). Sgk1 hnRNA and mRNA levels in 
the stressed drug-treated animals were similar to those in the stressed vehicle-treated 
animals but these levels were not different from those in the drug-treated control animals 
(Fig. 2F, G). Clearly, metyrapone seems to produce distinct effects which are condition-, gene- 
and transcript-dependent. 
 
Adrenalectomy abolishes stress-evoked MR and GR binding to GREs within GC target genes 
The experiments applying the CORT synthesis inhibitor metyrapone showed that there was 
incomplete inhibition of synthesis as well as unexpected results with regard to MR and GR 
GRE-binding and RNA responses. Therefore, we decided to study these molecular GC 
endpoints under conditions of complete surgical removal of the source of CORT, i.e. ADX. We 




completely abolished the FS-induced increase in CORT levels (Fig. 3A). Both intact and sham 
rats showed strong CORT responses to FS and this response was slightly but significantly 
higher in the sham-operated rats than in the intact animals (Fig. 3A). Baseline AM (BLAM) 
CORT levels were very low and not significant different between ADX, sham or intact rats (Fig. 
3A). The BLAM groups in this set of experiments were not termed ‘controls’ to distinguish 
them from the control groups in the metyrapone experiments which had received injections 
as part of the experimental protocol.  
Regarding MR and GR binding to GREs within target genes, significant increases were found 
after stress at all genes in both intact and sham groups (Fig. 3B-G), except for the stress-
induced MR binding to the Sgk1 GRE in the sham group that just escaped significance 
(P=0.053, post-hoc Bonferroni test (Fig. 3F). ADX abrogated all stress-evoked increases in MR 
and GR binding to GREs (Fig. 3B-G). Furthermore, under BLAM conditions, MR binding to GREs 
within Per1 and Sgk1 in ADX rats was significantly lower than levels observed under such 
conditions in intact and/or sham animals (Fig. 3D, F). As expected, GR binding to GREs under 
BLAM conditions did not differ at any gene loci between groups.  
Together, these results show that ADX results in a consistent abrogation of the effects of 
stress on MR and GR binding to GREs within the GC target genes Fkbp5, Per1 and Sgk1.  
 
Adrenalectomy abrogates stress-induced GC target gene transcriptional responses 
Using the same experimental design as in the previous experiment, except for killing the rats 
at 60min after FS, we studied the effects of ADX on baseline and stress-induced gene 




CORT response to stress (Fig. 4A). The stress-induced plasma CORT response was higher in 
the sham rats than in the intact animals (Fig. 4A) which is consistent with the difference in 
responses at FS30 (Fig. 3A).  
FS stress resulted in significant increases in Fkbp5 hnRNA, Per1 hnRNA and mRNA, and Sgk1 
hnRNA and mRNA in the hippocampus of intact and sham rats (Fig. 4B, D-G); thereby, intact 
and sham animals showing comparable responses to stress. Clearly, ADX completely 
abolished these stress-evoked RNA responses (Fig. 4B, D-G). Removal of the adrenal glands 
however had no effect on the BLAM levels of these RNAs. Consistent with previous 
observations (Fig. 3C; [14]), there was no effect of stress apparent on hippocampal Fkbp5 
mRNA levels in the intact and sham rats. ADX resulted in a significant decrease in the BLAM 
levels of this mRNA, indicating that, in addition to stress, Fkbp5 gene transcription is regulated 












This study reveals unexpected genomic effects in the hippocampus following metyrapone 
treatment which appear to be unrelated to the drug’s effects on GC secretion. Despite 
failing to exert any effect on CORT levels under unstressed control conditions, drug 
treatment resulted in enhanced MR and GR to GRE binding within the GC target genes and 
increased transcriptional activity of these genes. Metyrapone reduced stress-induced GC 
levels, however without leading to full abrogation of this stress response. Under these 
conditions, drug treatment led to a partial inhibition of MR and GR to GRE binding and 
transcriptional activation, in particular if responses were compared with the respective 
vehicle-treated control groups. Thus, under stress conditions, the observed changes in MR 
and GR binding and transcriptional activity after metyrapone treatment appear to be the 
combined result of unspecific, GC-unrelated effects (discernible under control conditions) 
and GC-reducing effects. In particular regarding effects on transcriptional activity, the drug 
effects were gene-dependent. In contrast, ADX abolished the stress effects on plasma CORT 
as well as hippocampal MR and GR to GRE binding and transcriptional responses. These 
clear-cut genomic effects directly correspond with the absence of endogenous GCs as a 
result of the adrenal extirpation. 
Our ChIP data show that vehicle-treated control rats as well as intact and sham rats present 
very low MR and GR binding to GREs within the classical GC target genes Fkbp5, Per1 and 
Sgk1. FS resulted in significant increases in receptor binding to these GREs. These results are 
highly consistent with our previously reported findings in (untreated) intact rats [14]. 
Similarly, the FS-induced RNA responses in the vehicle-treated, intact and sham rats 




abolished the stress-evoked responses in receptor binding and gene transcription indicating 
that the presence of endogenous GCs is crucial for these responses. Earlier work has shown 
that CORT is metabolized rapidly, and MRs and GRs become unoccupied within a few hours 
post-ADX [17]. Thus, similarly, in the present study in the case of ADX, MRs and GRs will 
have become devoid of ligand shortly after withdrawal of CORT from the drinking water. 
Accordingly, we show here for the first time that these receptors indeed require ligand 
binding in order to interact with GREs in vivo after stress. 
We started this study on the role of endogenous GCs in baseline and stress-induced 
genomic responses in GC target genes by using the CORT-synthesis inhibitor metyrapone. 
Our data show, however, that treatment with this drug produced contradictory results with 
regard to plasma CORT levels versus MR and GR to GRE binding and RNA responses 
concerning the genes Fkbp5, Per1 and Sgk1. Metyrapone attenuated, albeit not abolished, 
the stress-induced increases in plasma CORT and GRE-binding of MR and GR. In view of the 
drug’s effect on GC levels, a reduction in stress-induced receptor binding was expected but 
was not as stark as may have been predicted given the strong reduction in stress-evoked 
CORT levels. Surprisingly, however, although metyrapone produced no changes in 
circulating GC levels in the unstressed control rats, drug treatment resulted in significant 
increases in MR binding and also to some extent GR binding (i.e. Fkbp5) to GREs within the 
target genes. These observations are rather puzzling as CORT levels were unchanged. A 
possible reason for the elevated MR binding after metyrapone treatment may be 11-
deoxycorticosterone (DOC), the CORT precursor known to accumulate after inhibition of 
11β-hydroxylase [18]. DOC is a mineralocorticoid with very high affinity for binding to MR 
[19] and is thought to be responsible for some of the side effects of metyrapone treatment 




Cushing’s disease [20]. As hippocampal MRs are at least 75-80% occupied under early 
morning baseline conditions [17, 21], DOC could bind to the 20-25% rest-capacity in MR 
binding potentially resulting in the enhanced MR to GRE binding observed after 
metyrapone. Whilst this perhaps may be an explanation for the increased MR to GRE 
binding after metyrapone under control conditions, it is very unlikely to explain the elevated 
GR to GRE binding after drug administration under these conditions. Increased DOC levels 
after metyrapone are irrelevant for GR as this steroid has very low affinity for binding to 
GRs. Based on our recent study [14], it may be argued that possibly increased GR to GRE 
binding may be indirectly brought about through heterodimerization with MR whose GRE-
binding is found to be enhanced after metyrapone. This is, however, an unlikely possibility 
as, under these control conditions, the occupancy of GRs by CORT will be very low and thus 
the receptor would not be in a GRE-binding state [17, 21]. Thus, presently, the mechanisms 
underlying the increased MR and GR to GRE binding are unclear. Elevated post-metyrapone 
DOC levels can partially provide an explanation. Most likely, other, as yet unknown, effects 
of the enzyme inhibitor are very likely to play a role in the observations made in the drug-
treated control rats. 
 In view of the diverse effects of metyrapone on the binding of MR and GR to Fkbp5, Per1 
and Sgk1 GREs under control and stress conditions, it is difficult to explain the effects of the 
drug on the responses in hnRNA and mRNA of these genes. The increased hnRNA and mRNA 
levels observed under control conditions after metyrapone administration appear to 
correspond with the enhanced MR and GR to GRE binding under these conditions. The 
stress-induced responses in hnRNA after metyrapone treatment are highly varied. Hence, 
we found that the drug inhibited, enhanced, or had no effects on the stress-induced 




not to point to a single, consistent mechanism underpinning the gene transcriptional effects 
of metyrapone. Factors contributing to these distinct effects may include differences in the 
relative contribution of MR and GR to gene activity, inherent differences between genes 
regarding transcriptional regulation (e.g. multiple GREs within genes or in enhancer regions, 
chromatin looping mechanisms), and differences in the timeline of transcriptional activation 
and RNA processing. ADX, in contrast, produced highly consistent effects on both receptor 
to GRE binding as well as gene transcriptional responses.  
The aim of the present study was to investigate the role of endogenous GCs in the effects of 
an acute stressful challenge (FS) on MR and GR binding to GC target genes and the 
transcriptional responses of these genes. To block endogenous GCs we first used the CORT-
synthesis inhibitor metyrapone in order to learn whether this pharmacological approach 
would be an appropriate alternative to the surgical procedure of ADX. Our data show that 
the drug produces diverse genomic effects that can only partially be explained by its CORT-
reducing activity and accumulation of DOC. In particular, its effects on gene transcriptional 
activity were highly diverse. In contrast, the effects of ADX on the GC-dependent genomic 
endpoints were unambiguous. Importantly, the genes Fkbp5, Per1 and Sgk1 in the 
hippocampus play important roles in GC sensitivity and negative feedback regulation, 
circadian regulation of physiological and behavioral activities, and neuroplasticity processes 
underlying learning and memory, respectively [22-24]. Moreover, these genes as well as 
many other GC-regulated genes play important roles in many organs throughout the entire 
body. Therefore, evidently the unexpected genomic effects of metyrapone question its 
suitability for conducting studies on the GC dependency of physiological and behavioral 




interpret or may be liable to misinterpretation. We conclude that ADX is (still) the method 
of choice to elucidate the role of endogenous GC secretion in physiology and behavior. 
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Legends to the Figures 
Fig. 1. Plasma CORT levels (A) and hippocampal MR and GR binding to GREs within GC target 
genes (B-G) under control and stress conditions following metyrapone treatment. Rats were 
treated with vehicle or metyrapone (100mg/kg) as described in the Methods section and 
Suppl. Figure 1. Rats were killed 30 min (FS30) after the start of FS (15 min in 25 °C-water). In 
parallel, separate groups of rats were killed as unstressed controls. Plasma CORT levels were 
determined in trunk blood (A) and expressed as ng/ml (mean ± SEM, n = 8 per group). 
Hippocampus tissues were collected for MR and GR ChIP and qPCR analysis. Tissues of 2 rats 
were pooled for each chromatin preparation. Enrichment of MR and GR were determined at 
GREs within Fkbp5 (B, C), Per1 (D, E) and Sgk1 (F, G), as indicated. Enrichment was expressed 
as Bound/Input; mean ± SEM, n = 3-4. Data were analyzed by two-way ANOVA followed by 
post-hoc Bonferroni tests, if appropriate. Two-way ANOVA analysis: A: Effect of (drug) 
treatment: F(2, 42)=120.2, P<0.0001, Effect of stress: F(1, 42)=388.4, P<0.0001, Interaction: 
F(2, 42)=133.7, P<0.0001; B: Effect of treatment: F(2, 17)=5.603, P=0.0135, Effect of stress: 
F(1, 17)=161.6, P<0.0001, Interaction: F(2, 17)=22.43, P<0.0001; C: Effect of treatment: F(2, 
16)=4.629, P=0.0259, Effect of stress: F(1, 16)=92.65, P<0.0001, Interaction: F(2, 16)=20.54, 
P<0.0001; D: Effect of treatment: F(2, 17)=1.363, P=0.2825, Effect of stress: F(1, 17)=62.50, 
P<0.0001, Interaction: F(2, 17)=9.143, P=0.0020; E: Effect of treatment: F(2, 18)=0.6013, 
P=0.5587, Effect of stress: F(1, 18)=36.53, P<0.0001, Interaction: F(2, 18)=6.187, P=0.0090; F: 
Effect of treatment: F(2, 17)=3.297, P=0.0616, Effect of stress: F(1, 17)=50.47, P<0.0001, 
Interaction: F(2, 17)=9.787, P=0.0015; G: Effect of treatment: F(2, 18)=0.7892, P=0.4693, 
Effect of stress: F(1, 18)=48.13, P<0.0001, Interaction: F(2, 18)=4.058, P=0.0351; *P < 0.05 




treated group; E: P=0.093, Met 2x100/Control vs Vehicle/Control; F: P=0.085, Met 
2x100/FS30 vs Vehicle/FS30; G: P=0.095, Met 2x100/FS30 vs Vehicle/FS30, post-hoc 
Bonferroni test. Abbreviations: Met 100, a single injection of 100 mg/kg metyrapone; Met 2x 
100, two injections of 100 mg/kg metyrapone 
 
Fig. 2. Plasma CORT levels (A) and hippocampal GC target gene expression (B-G) under 
control and stress conditions following metyrapone treatment. Rats were treated with 
vehicle or metyrapone (100mg/kg) as described in the Methods section and Suppl. Figure 1. 
Rats were killed 60 min (FS60) after the start of FS (15 min in 25 °C-water). In parallel, separate 
groups of rats were killed as unstressed controls. Plasma CORT levels were determined in 
trunk blood (A) and expressed as ng/ml (mean ± SEM, n = 6 per group). Hippocampus tissues 
were collected for RNA extraction and qPCR analysis. Levels of RNA expression (Fkbp5 hnRNA 
and mRNA, B, C, respectively; Per1 hnRNA and mRNA, D, E; Sgk1 hnRNA and mRNA, F, G) were 
expressed as fold change relative to the vehicle-treated group (mean ± SEM, n = 6 per group). 
For more information, see Methods section. Data were analyzed by two-way ANOVA followed 
by post-hoc Bonferroni tests, if appropriate. Two-way ANOVA analysis: A: Effect of (drug) 
treatment: F(1, 19)=10.31, P=0.0046, Effect of stress: F(1, 19)=38.39, P<0.0001, Interaction: 
F(1, 19)=18.75, P=0.0004; B: Effect of (drug) treatment: F(1, 20)=28.42, P<0.0001, Effect of 
stress: F(1, 20)=212.9, P<0.0001, Interaction: F(1, 20)=199.6, P<0.0001; C: Effect of (drug) 
treatment: F(1, 20)=27.48, P<0.0001, Effect of stress: F(1, 20)=0.07551, P=0.7863, Interaction: 
F(1, 20)=1.527, P=0.2309; D: Effect of (drug) treatment: F(1, 20)=56.49, P<0.0001, Effect of 
stress: F(1, 20)=52.48, P<0.0001, Interaction: F(1, 20)=1.027, P=0.3229; E: Effect of (drug) 
treatment: F(1, 20)=21.13, P=0.0002, Effect of stress: F(1, 20)=29.65, P<0.0001, Interaction: 




stress: F(1, 20)=46.63, P<0.0001, Interaction: F(1, 20)=28.89, P<0.0001; G: Effect of (drug) 
treatment: F(1, 20)=32.04, P<0.0001, Effect of stress: F(1, 20)=81.45, P<0.0001, Interaction: 
F(1, 20)=48.42, P<0.0001; *P < 0.05 compared with the respective Control group; $P < 0.05 
compared with the respective vehicle-treated group, post-hoc Bonferroni test 
 
Fig. 3. Plasma CORT levels (A) and hippocampal MR and GR binding to GREs within GC target 
genes (B-G) under control and stress conditions after ADX. Rats were ADX, sham-ADX or left 
untouched as described in the Methods section and Suppl. Figure 1. Rats were killed 30 min 
(FS30) after the start of FS (15 min in 25 °C-water). In parallel, separate groups of rats were 
killed under baseline AM (BLAM) conditions. Plasma CORT levels were determined in trunk 
blood (A) and expressed as ng/ml (mean ± SEM, n = 8 per group). Hippocampus tissues were 
collected for MR and GR ChIP and qPCR analysis. Tissues of 2 rats were pooled for each 
chromatin preparation. Enrichment of MR and GR were determined at GREs within Fkbp5 (B, 
C), Per1 (D, E) and Sgk1 (F, G), as indicated. Enrichment was expressed as Bound/Input; mean 
± SEM, n = 3-4. Data were analyzed by two-way ANOVA followed by post-hoc Bonferroni tests, 
if appropriate. Two-way ANOVA analysis: A: Effect of treatment: F(2, 18)=87.11, P<0.0001, 
Effect of stress: F(1, 18)=325.8, P<0.0001, Interaction: F(2, 18)=85.40, P<0.0001; B: Effect of 
treatment: F(2, 18)=69.81, P<0.0001, Effect of stress: F(1, 18)=177.3, P<0.0001, Interaction: 
F(2, 18)=38.41, P<0.0001; C: Effect of treatment: F(2, 18)=32.31, P<0.0001, Effect of stress: 
F(1, 18)=108.0, P<0.0001, Interaction: F(2, 18)=26.47, P<0.0001; D: Effect of treatment: F(2, 
18)=31.32, P<0.0001, Effect of stress: F(1, 18)=18.77 P=0.0004, Interaction: F(2, 18)=3.366, 
P=0.0573; E: Effect of treatment: F(2, 18)=54.47, P<0.0001, Effect of stress: F(1, 18)=169.0, 




P<0.0001, Effect of stress: F(1, 17)=10.79, P=0.0044, Interaction: F(2, 17)=1.990, P=0.1673; G: 
Effect of treatment: F(2, 18)=36.01, P<0.0001, Effect of stress: F(1, 18)=101.3, P<0.0001, 
Interaction: F(2, 18)=18.86, P<0.0001; *P < 0.05 compared with the respective BLAM group; 
$P < 0.05 compared with the respective Intact group; #, P<0.05 compared with the respective 
Sham group; F: P=0.083, BLAM/ADX vs BLAM/Intact, P=0.053, FS30/Sham vs BLAM/Sham, 
post-hoc Bonferroni test 
 
Fig. 4. Plasma CORT levels (A) and hippocampal GC target gene expression (B-G) under 
control and stress conditions after ADX. Rats were ADX, sham or left untouched as described 
in the Methods section and Suppl. Figure 1. Rats were killed 60 min (FS60) after the start of 
FS (15 min in 25 °C-water). In parallel, separate groups of rats were killed under baseline AM 
(BLAM) conditions. Plasma CORT levels were determined in trunk blood (A) and expressed as 
ng/ml (mean ± SEM, n = 6 per group). Hippocampus tissues were collected for RNA extraction 
and qPCR analysis. Levels of RNA expression (Fkbp5 hnRNA and mRNA, B, C, respectively; Per1 
hnRNA and mRNA, D, E; Sgk1 hnRNA and mRNA, F, G) were expressed as fold change relative 
to the vehicle-treated group (mean ± SEM, n = 6 per group). For more information, see 
Methods section. Data were analyzed by two-way ANOVA followed by post-hoc Bonferroni 
tests, if appropriate. Two-way ANOVA analysis: A: Effect of treatment: F(2, 29)=5.196, 
P=0.0118, Effect of stress: F(1, 29)=4.540, P=0.0417, Interaction: F(2, 29)=1.874, P=0.1717; B: 
Effect of treatment: F(2, 29)=32.80, P<0.0001, Effect of stress: F(1, 29)=126.4, P<0.0001, 
Interaction: F(2, 29)=25.47, P<0.0001; C: Effect of treatment: F(2, 29)=21.02, P<0.0001, Effect 
of stress: F(1, 29)=2.809, P=0.1045, Interaction: F(2, 29)=0.300, P=0.7431; D: Effect of 




F(2, 29)=6.069, P=0.0063; E: Effect of treatment: F(2, 29)=13.29, P<0.0001, Effect of stress: 
F(1, 29)=91.85, P<0.0001, Interaction: F(2, 29)=13.26, P<0.0001; F: Effect of treatment: F(2, 
29)=17.45, P<0.0001, Effect of stress: F(1, 29)=49.30, P<0.0001, Interaction: F(2, 29)=15.18, 
P<0.0001; G: Effect of treatment: F(2, 29)=60.00, P<0.0001, Effect of stress: F(1, 29)=189.7, 
P<0.0001, Interaction: F(2, 29)=51.26, P<0.0001; *P < 0.05 compared with the respective 
BLAM group; $P < 0.05 compared with the respective Intact group; #, P<0.05 compared with 
the respective Sham group, post-hoc Bonferroni test. 
 
Supplementary Fig. 1. Experimental schedule of the experiments involving metyrapone 
treatment. Rats were injected once (injection at 0 min) or twice (injections at 0 min and 90 
min) with 100mg/kg metyrapone or vehicle which was followed by a FS challenge or not 
(home cage). After FS, the rats were returned to their home cage until they were killed for 
blood and tissue collection, as indicated. The data of the experiment described in the top 
aspect of the table are depicted in Figure 1 whereas the data of the experiment described in 
the bottom part are shown in Figure 2.  
 
Supplementary Fig. 2. Hippocampal HKG gene expression under control and stress 
conditions following metyrapone treatment. Rats were treated with vehicle or metyrapone 
(100mg/kg) as described in the Methods section and Suppl. Figure 1. Rats were killed 60 min 
(FS60) after the start of FS (15 min in 25 °C-water). In parallel, separate groups of rats were 
killed as unstressed controls. Hippocampus tissues were collected for RNA extraction and 
qPCR analysis. Expression of the housekeeping genes Hprt1 (A) and Ywhaz (B), based on 
qPCR cycle threshold (CT) values, remained stable across treatment groups (mean ± SEM, n = 
30 
6 per group). Stability was confirmed by a lack of statistical difference in the two-way 
ANOVA. Two-way ANOVA analysis: A: Effect of (drug) treatment: F(1, 20)=1.894, P=0.1840, 
Effect of stress: F(1, 20)=1.643, P=0.2145, Interaction: F(1, 20)=1.094, P=3082; B: Effect of 
(drug) treatment: F(1, 20)=1.128, P=0.3009, Effect of stress: F(1, 20)=1.608, P=0.2194, 
Interaction: F(1, 20)=1.045, P=0.3189. 
Supplementary Fig. 3. Hippocampal HKG gene expression under control and stress 
conditions after ADX. Rats were ADX, sham or left untouched as described in the Methods 
section. Rats were killed 60 min (FS60) after the start of FS (15 min in 25 °C-water). In 
parallel, separate groups of rats were killed under baseline AM (BLAM) conditions. 
Hippocampus tissues were collected for RNA extraction and qPCR analysis. Expression of the 
housekeeping genes Hprt1 (A) and Ywhaz (B), based on qPCR cycle threshold (CT) values, 
remained stable across treatment groups (mean ± SEM, n = 5-6 per group). Stability was 
confirmed by a lack of statistical difference in the two-way ANOVA. Two-way ANOVA 
analysis: A: Effect of treatment: F(2, 29)=0.8653, P=0.4315, Effect of stress: F(1, 
29)=0.06723, P=0.7973, Interaction: F(2, 29)=0.5806, P=0.5659; B: Effect of treatment: F(2, 
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